What we know and what we do not
At 72 weeks, tirzepatide's safety profile is well-characterized and favorable. Beyond 72 weeks, we have post-market surveillance data from ~3 years of real-world use but no very long-term controlled data. The drug's benefit-risk profile at current timeframes is strongly positive.
Tirzepatide (Zepbound, Mounjaro) has been in clinical use since June 2022. Phase 3 trials ran to 72 weeks. That gives us approximately 18 months of controlled trial data plus roughly 3 years of post-market surveillance. Here is what that combined evidence shows about long-term safety.
Phase 3 Safety Data (72 Weeks)
| Adverse Event | Tirzepatide Rate | Placebo Rate |
|---|---|---|
| Any GI event | ~75% | ~42% |
| Serious adverse events | ~9% | ~10% |
| Discontinuation due to AE | ~7% | ~3% |
| Injection site reaction | ~4% | ~1% |
| Hypoglycemia (non-diabetic) | <1% | <1% |
| Gallbladder events | ~1.4% | ~0.6% |
Key Safety Considerations
Thyroid: Like all GLP-1 agonists, tirzepatide carries a boxed warning for thyroid C-cell tumors based on rodent studies. No increased incidence of medullary thyroid carcinoma has been detected in humans in trial or post-market data. The warning reflects a precautionary approach, not a confirmed human signal. The drug is contraindicated in patients with personal or family history of MTC or MEN2.
Pancreatitis: GLP-1 drugs have historically been associated with pancreatitis concerns. Phase 3 tirzepatide data did not show a statistically significant increase in pancreatitis. Post-market surveillance continues to monitor this.
Gallbladder: Significant weight loss of any cause increases gallstone risk. Tirzepatide showed a small increase in gallbladder events (~1.4% vs 0.6% placebo). This is a known phenomenon with rapid weight loss, not specific to GLP-1s.
Gastrointestinal: The most common side effects (~75%) are GI-related. Most are transient and dose-escalation-related. Serious GI events were not more common than placebo.
Work with a provider who monitors for safety signals as part of ongoing care.
Get My MatchWhat Remains Unknown
We do not have: controlled data beyond 72 weeks; cardiovascular outcomes data (SURMOUNT-CVOT is ongoing); very long-term (10+ year) real-world data; or population-level rare adverse event data that requires millions of patient-years to detect. These unknowns are not reasons to avoid the drug — they reflect where research currently stands.
See: long-term GLP-1 use, which GLP-1 has fewest side effects.
Frequently Asked Questions
Is tirzepatide safe long-term?
Based on 72-week Phase 3 data and ~3 years of real-world use, tirzepatide's safety profile is favorable. Very long-term data beyond 5 years is not yet available, but no safety signals have emerged that contraindicate ongoing use.
Does tirzepatide cause thyroid cancer?
No documented increase in medullary thyroid carcinoma has been detected in human trials or post-market surveillance. The boxed warning is based on rodent studies and reflects a precautionary regulatory approach. The drug is contraindicated in people with personal or family history of MTC or MEN2.
What is the most serious side effect of tirzepatide?
Serious adverse events occurred at similar rates in tirzepatide and placebo arms (~9% vs ~10%) in Phase 3. GI side effects are the most common reason for discontinuation. There is no safety signal that emerges clearly as the 'most serious' in trial data.
Ready to find your match?
Answer 5 quick questions and see licensed GLP-1 programs available in your state - matched to your budget. Free. No obligation.
Get My Match - Free